21:06 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
23:31 , Oct 11, 2018 |  BC Week In Review  |  Company News

Philadelphia groups partner to target Tregs for lung cancer

AUM LifeTech Inc. (Philadelphia, Pa.), Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania partnered to develop an RNA silencing immunotherapy to treat lung cancer. The therapeutic, which...
22:19 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health...
00:12 , Oct 10, 2018 |  BC Extra  |  Preclinical News

In utero base editing corrects metabolic birth defect

Researchers from Children's Hospital of Philadelphia and University of Pennsylvania opened the door to prenatal genome editing by using a relatively new CRISPR-based approach called base editor 3 to correct tyrosinemia type I, a rare...
20:34 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Adcetris meets in Phase III for first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin plus chemotherapy met the primary and all key secondary endpoints in the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing...
19:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

New risdiplam data show improvements in developmental milestones

PTC Therapeutics Inc. (NASDAQ:PTCT) and Genentech Inc. reported updated data from part I of the two-part Phase II/III FIREFISH and SUNFISH trials of risdiplam (RG7916) to treat spinal muscular atrophy (SMA) that highlighted improvements in...
23:26 , Oct 3, 2018 |  BC Extra  |  Clinical News

New risdiplam data show improvements in developmental milestones

PTC Therapeutics Inc. (NASDAQ:PTCT) and Genentech Inc. reported updated data from part I of the two-part Phase II/III FIREFISH and SUNFISH trials of risdiplam (RG7916) to treat spinal muscular atrophy (SMA) that highlighted improvements in...
02:01 , Sep 29, 2018 |  BioCentury  |  Politics, Policy & Law

PROs in prime time

A recommendation by CMS’s MEDCAC catapults the collection of PRO data to the postmarket setting from their more familiar spot in clinical development. CAR T leaders Novartis AG and Gilead Sciences Inc., however, are not...